Voyager Therapeutics (VYGR) Downgraded By Wedbush from “Outperform”; Och-Ziff Capital Management Group (OZM) Had 4 Analysts Last Week

Among 10 analysts covering Och-Ziff Capital Management Group (NYSE:OZM), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Och-Ziff Capital Management Group had 34 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, May 31. The firm has “Hold” rating by Keefe Bruyette & Woods given on Wednesday, August 2. RBC Capital Markets maintained the shares of OZM in report on Wednesday, February 3 with “Outperform” rating. The company was maintained on Monday, September 25 by Jefferies. The firm has “Market Perform” rating given on Wednesday, November 4 by Keefe Bruyette & Woods. As per Thursday, August 25, the company rating was downgraded by Citigroup. Wood downgraded the shares of OZM in report on Monday, July 11 to “Market Perform” rating. Compass Point upgraded the shares of OZM in report on Thursday, September 29 to “Buy” rating. The firm has “Hold” rating by Keefe Bruyette & Woods given on Monday, September 4. The company was maintained on Wednesday, August 2 by Jefferies. See Och-Ziff Capital Management Group LLC (NYSE:OZM) latest ratings:

20/02/2018 Broker: Citigroup Rating: Buy New Target: $4.5 Upgrade
04/10/2017 Broker: Jefferies Rating: Hold Old Target: $3 New Target: $3.5 Maintain
25/09/2017 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain

Among 12 analysts covering Voyager Therap… (VYGR), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Voyager Therap… has $39 highest and $1300 lowest target. $28.22’s average target is 4.95% above currents $26.89 stock price. Voyager Therap… had 20 analyst reports since May 20, 2016 according to SRatingsIntel. Wedbush maintained it with “Buy” rating and $29.0 target in Wednesday, February 21 report. Evercore initiated Voyager Therapeutics, Inc. (NASDAQ:VYGR) on Wednesday, August 16 with “Buy” rating. BTIG Research maintained Voyager Therapeutics, Inc. (NASDAQ:VYGR) on Tuesday, January 23 with “Buy” rating. BTIG Research maintained Voyager Therapeutics, Inc. (NASDAQ:VYGR) rating on Tuesday, February 20. BTIG Research has “Buy” rating and $32.0 target. The rating was initiated by Piper Jaffray on Tuesday, November 28 with “Buy”. The rating was maintained by BTIG Research with “Buy” on Friday, March 9. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, September 6. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, January 23. The rating was maintained by Cowen & Co on Tuesday, August 8 with “Buy”. Morgan Stanley maintained the shares of VYGR in report on Wednesday, February 21 with “Overweight” rating.

The stock decreased 0.11% or $0.03 during the last trading session, reaching $26.89. About 1.44 million shares traded or 248.26% up from the average. Voyager Therapeutics, Inc. (VYGR) has declined 18.89% since March 12, 2017 and is downtrending. It has underperformed by 35.59% the S&P500.

Analysts await Voyager Therapeutics, Inc. (NASDAQ:VYGR) to report earnings on March, 21. They expect $-0.73 EPS, down 28.07% or $0.16 from last year’s $-0.57 per share. After $-0.89 actual EPS reported by Voyager Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -17.98% EPS growth.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company has market cap of $845.68 million. The companyÂ’s lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. It currently has negative earnings. The Company’s preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for HuntingtonÂ’s disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, AlzheimerÂ’s disease; and VY-NAV01 for severe chronic pain.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.14, from 1.07 in 2017Q2. It improved, as 12 investors sold Och-Ziff Capital Management Group LLC shares while 15 reduced holdings. 11 funds opened positions while 18 raised stakes. 84.98 million shares or 0.51% more from 84.55 million shares in 2017Q2 were reported. Hightower Limited holds 0% or 43,075 shares in its portfolio. Sterneck Cap Mngmt Ltd invested 0.75% of its portfolio in Och-Ziff Capital Management Group LLC (NYSE:OZM). Greenwich Wealth Mngmt Lc has 24,000 shares for 0.01% of their portfolio. Sg Americas Securities Limited Liability holds 0.06% in Och-Ziff Capital Management Group LLC (NYSE:OZM) or 2.00 million shares. Harvest Mngmt Ltd accumulated 10,000 shares. 456,792 are held by Freestone Capital Holdings Lc. Manufacturers Life Ins The has invested 0% of its portfolio in Och-Ziff Capital Management Group LLC (NYSE:OZM). Virtu Fincl Ltd Limited Liability Company reported 42,929 shares. Artemis Investment Mgmt Llp holds 0.21% or 3.24 million shares in its portfolio. Mariner Wealth Advisors Ltd Liability Corporation invested 0.02% of its portfolio in Och-Ziff Capital Management Group LLC (NYSE:OZM). Illinois-based Tru Department Mb Savings Bank N A has invested 0% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Wells Fargo Co Mn owns 0% invested in Och-Ziff Capital Management Group LLC (NYSE:OZM) for 247,235 shares. Spectrum Mngmt Group Inc Inc accumulated 179 shares. Gamco Investors Et Al invested 0% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Oppenheimer And reported 0% in Och-Ziff Capital Management Group LLC (NYSE:OZM).

The stock increased 1.82% or $0.05 during the last trading session, reaching $2.8. About 501,192 shares traded. Och-Ziff Capital Management Group LLC (NYSE:OZM) has declined 36.39% since March 12, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.

Och-Ziff Capital Management Group LLC is a publicly owned hedge fund sponsor. The company has market cap of $1.30 billion. The firm provides investment advisory services for its clients. It has a 28.57 P/E ratio. It primarily caters to institutional investors which include pension funds, fund-of-funds, foundations and endowments, firms and other institutions, private banks and family offices.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: